Avatrombopag - Swedish Orphan Biovitrum
Alternative Names: AKR-501; AKR-501 monomaleate; Avatrombopag maleate; DOPTELET; E-5501; Su Ke Xin; YM-477Latest Information Update: 25 Sep 2024
At a glance
- Originator Astellas Pharma
- Developer Dova Pharmaceuticals; Eisai Co Ltd; Shanghai Fosun Pharmaceutical; Swedish Orphan Biovitrum
- Class Antithrombotics; Piperazines; Piperidines; Pyridines; Small molecules; Thiazoles
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Idiopathic thrombocytopenic purpura; Thrombocytopenia
Most Recent Events
- 13 Jun 2024 Efficacy and adverse events data from a phase-III clinical trials in Thrombocytopenia presented at the 29th Congress of the European Haematology Association (EHA-2024)
- 09 Apr 2024 Swedish Orphan Biovitrum announces intention to submit NDA to Japan, Pharmaceuticals and Medical Devices Agency for Idiopathic thrombocytopenic purpura in 2024
- 31 Dec 2023 Launched for Idiopathic thrombocytopenic purpura (Treatment-experienced) in Australia (PO) prior to December 2023